Congo Says Ebola Deaths Have Passed 1,700 as Outbreak Outpaces Response

Congo's Ebola Deaths Pass 1,700 as Response Struggles to Keep Up

Ebola has killed more than 1,700 people in eastern Democratic Republic of Congo since May. As of Tuesday, August 4, the Congolese government reported 3,802 cases and 1,707 deaths^[1]. The outbreak was declared on May 15 and is caused by the Bundibugyo strain of the virus^[1][2].

That strain matters more than it might seem. The vaccines and drugs that exist for Ebola were built for a different strain, called Zaire, which drove the major outbreaks of 2014 and 2018^[1][6]. Nothing is approved yet for Bundibugyo. Doctors are treating patients with supportive care — fluids, monitoring, managing symptoms — while two experimental drugs and one vaccine candidate are tested alongside them, too late to change the course of this outbreak even if they work^[2][6].

Here is the number that worries responders most: nearly 80% of new cases are turning up in people who were never on a watch list^[1]. Contact tracing is how outbreaks like this are normally beaten back. Workers find everyone an infected person touched, then monitor those people for 21 days, the outer edge of how long the virus can incubate before symptoms show. When most new cases come from outside that list, it means the virus is spreading through chains nobody mapped in time. Africa CDC's director-general, Jean Kaseya, has said he cannot yet predict when the outbreak will peak^[1].

A Funding Gap That Predates the Outbreak by a Year

Two numbers in this story do not agree, and the gap between them is itself part of the story. The World Health Organization's own confirmed-case count put the toll at 2,124 cases and 828 deaths as of July 15^[21]. Congo's government count, which also includes probable and suspected cases the WHO count leaves out, reached 3,802 cases and 1,707 deaths by August 4^[1]. Some of the difference is definitions. Some of it is simply time passing between the two counts. No single outlet covering this story has laid out clearly which is which.

A separate and more contested gap concerns money and timing. U.S. government funding for outbreak preparedness in eastern Congo — the surveillance networks, labs, and community outreach that catch outbreaks early — largely ended in March 2025, after the Trump administration dismantled USAID^[5][18]. The outbreak was declared more than a year later, in May 2026. Aid workers and researchers argue that sequence is not a coincidence: the systems built to catch this kind of spread fast were gone before the virus showed up, which they say is exactly why so many cases are now being found outside contact-tracing lists^[1][5].

The administration and outlets sympathetic to it point to a different set of numbers: what the U.S. is doing right now. That is roughly $23 million committed to Ebola clinics and response work, plus $50 million pledged toward developing drugs and vaccines, with about 30 CDC staff in Congo and 100 more in Uganda^[1]. Set against that is a joint WHO and Africa CDC response plan that is short more than $400 million^[1][4]. Both figures are real. They just answer different questions — one is about what happened before the outbreak, the other about what is happening during it.

Why Washington and Kinshasa Are Arguing About Two Different Things

The argument over U.S. aid cuts is, underneath it, an argument about two different clocks. Surveillance systems — labs that can test fast, health workers who know the villages, trust built with communities before anyone gets sick — take years to build and only months to lose. That is why critics of the cuts say restoring money in 2026 cannot instantly rebuild a network that stopped operating in March 2025^[5][18]. It is also why defenders of the administration's approach say the more honest test is not the funding history but the response happening today, and that the real strategic question is what fills the gap if the U.S. steps back at all^[1][9].

That second question has an answer, and it involves China. Beijing has sent three successive medical expert teams to Congo, the first arriving in Kinshasa on June 2 and a third on August 1^[10][11]. Chinese state media frame this as South-South cooperation — assistance between countries that have both lived through epidemics, offered without the conditions that come with Western aid^[10]. The Washington Times has argued more bluntly that this is the real story: American aid cuts opening a door in a country that holds cobalt and copper reserves both Washington and Beijing want^[9]. Chinese coverage of its own teams does not mention American deployments at all, or the $400 million funding gap — an absence that lets Chinese aid appear to fill an empty space with no stated cause^[10][11].

For its part, the U.S. right-leaning press has largely told this story through a different lens: what happens if Ebola reaches American soil. Fox News coverage centers on the State Department's Level 4 travel advisory, issued in May, and a rule barring anyone who was in Congo within the last 21 days from boarding U.S.-bound commercial flights^[7][20]. Two American citizens have already tested positive for Ebola while working in Congo^[8]. Twenty-one days is not a random number here either — it is the same incubation window contact tracers use, chosen because someone past it without symptoms will not go on to develop the disease.

What Uganda's Success Shows About What Still Matters

Uganda offers a useful contrast. It had its own linked outbreak and declared it over on July 28, after 12 days with no new cases^[2]. That happened in a country with a functioning state and, crucially, no active war in the affected areas. Congo has neither advantage in Ituri and the Kivu provinces, where this outbreak has spread into territory partly held by the Rwanda-backed M23 rebel group^[16].

War sets a hard ceiling on what any amount of money can accomplish. Burial teams have been attacked, including one in Mongbwalu on June 17 whose five workers were taken hostage^[4][14]. An Ebola treatment center in Bunia was also attacked, and patients fled^[14]. No funding level makes a clinic safe while it's under attack, and that constraint holds regardless of which country is paying for the response. It is one of the few points in this story where the U.S. right and left, and the Congolese government itself, do not really disagree.

The Deeper Reason No Vaccine Exists for This Strain

One structural fact sits underneath all of this and predates the current political fight by decades. Ebola vaccines and treatments exist for the Zaire strain because that strain caused the outbreaks big enough to draw global attention and funding — most notably the 2014-16 West African epidemic. Bundibugyo, a rarer strain, never generated that kind of market pressure. Pharmaceutical development follows where the money and the outbreaks are, and until now Bundibugyo produced neither at a scale that justified the investment^[1][6].

That is why, even with $73 million in combined U.S. commitments and pledges now on the table, there is still no approved product for this strain^[1][2]. The WHO has fast-tracked trials of two experimental drugs, remdesivir and MBP134, which began enrolling patients on July 2, and Oxford has started a Phase 1 vaccine trial^[2][6]. Al Jazeera's coverage has centered this scientific effort, keeping WHO and African institutions at the front of the story rather than U.S. domestic politics^[6]. But trials take time outbreaks don't wait for. Whatever these trials find, it likely won't arrive in time to change what happens in Congo this year.

What the Numbers Still Don't Settle

By Congo's own count, about 45% of people who caught Ebola in this outbreak have died — 1,707 deaths out of 3,802 cases^[1]. That ratio is worth treating with caution. During an active outbreak, both mild cases that go unreported and deaths that occur outside health facilities can distort a case-fatality figure in either direction.

What isn't in dispute is that the virus is still finding new people faster than health workers can trace them, that a vaccine for this exact strain does not yet exist, and that a war is limiting where responders can safely go^[1][6][16]. Kaseya still won't say when the outbreak will peak^[1]. Until infection rates start falling within the existing contact-tracing net, rather than outside it, that answer probably isn't coming soon.